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http://dx.doi.org/10.1016/j.numecd.Abstract Obesity is characterized by the disproportionate growth of the components of body
size, including adipose tissue and lean body mass. Left ventricular (LV) hypertrophy often de-
velops, due to the coexistence of hemodynamic (cardiac workload) and non-hemodynamic com-
ponents (including body composition and activity of visceral fat). While the hypertrophy of
cardiomyocytes is produced by the hemodynamic load, through sarcomeric replication, there
is a parallel growth of non-muscular myocardial components, including interstitial fat infiltration
and accumulation of triglycerides in the contractile elements, which are thought to influence LV
geometric pattern. Thus, pure intervention on hemodynamic load is unlikely to result in effective
reduction of LV hypertrophy in obese. We review pathophysiology and prevalence of LV hypertro-
phy in obesity, with specific attention to LV geometric abnormalities and relations with body size.
ª 2013 Elsevier B.V. All rights reserved.Obesity is the disproportionate growth of components of
body size including adipose tissue and lean body mass,
characterized by a substantial increase of their ratio [1]
and alteration of body composition, which can reach the
level of a relative sarcopenia [2]. In relation to the body
distribution, adipose tissue presents different physiological
characteristics and metabolic activity. Subcutaneous fat is
almost metabolically silent and does not require substantial
blood supply, whereas visceral fat, including abdominal,1 7462025.
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2013.06.012mediastinal and epicardial adipose tissue, is metabolically
active and requires as much energy support as lean body
mass, to produce a number of compounds with autocrine,
paracrine and endocrine activities, influencing metabolism
and cardiovascular system [3,4].Pathophysiology of LV hypertrophy in obesity
Hemodynamic mechanisms (Fig. 1)
Because for the energy requirements visceral fat requires
a high blood minute supply, compared to normal-weightgeometry in obesity: Is it what we expect?, Nutrition, Metabolism
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Figure 1 Hemodynamic determinants of LV hypertrophy in
obesity. Increase in salt intake, circulating volume, cardiac
output and blood viscosity, as well as sleep apnea syndrome
(OSAS), sympathetic overdrive and renin angiotensin aldoste-
rone (RAS) systems may cause LV hypertrophy through devel-
opment of arterial hypertension or even directly.
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+ MODELindividuals, the cardiac workload in visceral obesity is
constantly increased [5e7]. This increase occurs as a conse-
quence of both increased heart rate and stroke work [7], due
to both volume overload and inadequate adaptation of pe-
ripheral resistance to the increased output [6]. Stroke work is
the most powerful stimulus to increasing LV mass [8] and in
obese individuals LV mass is in fact increased [9,10] (Fig. 2).
The biological mechanisms linking the hemodynamic
overload with the obesity-related myocardial geometric
abnormalities are complex and not entirely clarified. He-
modynamic of obesity is characterized by a predominant
volume overload with various degrees of pressure overload
related to the degree of increase in blood pressure, near
constant, even in the presence of normotension [11]. One
of the components of the expanding circulating volume in
obesity is the increased salt intake associated with food
overload, causing increased water retention [12,13]. InFigure 2 Panel A: relation between stroke work and LV mass ind
squares, dotted line) and adults (close lozenges, dashed line; ad
quadratic relation in the whole population with individual 90% con
mass index in normotensive normal-weight (dots) and overweight-o
quadratic relation and individual 90% confidence interval in the no
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& Cardiovascular Diseases (2013), http://dx.doi.org/10.1016/j.numecaddition, dietary salt intake is also associated with in-
creased myocardial thickness and left ventricular mass
[14,15], even independently of blood pressure.
The physiologic response of the renineangiotensin system
to the saline load is altered in young normotensive obese
subjects, compared to normal-weight peers [16]: suppres-
sion of plasma renin activity (PRA) and aldosterone after salt
loading, as well as the consequent increased urinary sodium
excretion are significantly reduced or delayed in insulin-
resistant obese, compared to normal-weight subjects [17].
Being LV hypertrophy the most potent predictor of car-
diovascular disease after age, the link between sodium
turnover and LV mass might at least in part explain the
association of salt intake with increased risk of stroke and
cardiovascular disease [18].
Non-hemodynamic mechanisms (Fig. 3)
The increase in LV mass is particularly linked to central fat
distribution [19]. Accumulation of visceral fat is thought to
affect signaling, transcription and remodeling of the heart
[20]. Visceral adipose tissue promotes a cascade of biological
events, including increased availability of angiotensinogen,
increased production of proteins with hemodynamic impact
(leptin, resistin, adipsin), reduced adiponectin and expres-
sion of a number of cytokines with direct inflammatory ef-
fect (TNF and IL6 family especially) [3,4]. Furthermore,
human adipocytes also produce potent mineralocorticoid-
releasing factors [21], which are likely associated with
development of arterial hypertension and with enhanced
pro-fibrotic activity [22].
Visceral adiposity also generates insulin resistance [23]
and stimulates sympathetic drive [5], other potent stimuli
for increasing LV mass [24,25]. However, though hyper-
insulinemia and insulin resistance have been reported to be
associated with LV mass in selected normotensive or hy-
pertensive population samples [25], we could not demon-
strate a clear independent association in the Strong Heartex in normotensive, normal-weight children/adolescents (open
apted from Ref. [11]). Continuous lines are the best fitting,
fidence interval. Panel B: relation between stroke work and LV
bese adults (open circles). Continuous lines are the best fitting,
rmal-weight population shown in Panel A.
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Figure 3 Non-hemodynamic determinants of LV hypertrophy in
obesity. Development of LV hypertrophy is influenced by non-
hemodynamic components altering structure and composition of
myocardium. These include inflammatory status, increased
plasma glucose and insulin resistance, increased epicardial fat,
adipokines, lipotoxicity and increased levels of circulating free
fatty acids (FFAs). Other mechanisms might also contribute by
altering hemodynamic load (gray background), in addition to a
direct cell effect (oxidative stress, endothelial disfunction, micro
and macrovascular disease, sympathetic overdrive and renin
angiotensin aldosterone (RAS) systems). CADZ coronary artery
disease.
N
o
rm
a
l 
w
e
ig
h
t
O
v
e
rw
e
ig
h
t
O
b
e
s
e
N
o
rm
a
l 
w
e
ig
h
t
O
v
e
rw
e
ig
h
t
O
b
e
s
e
0
20
40
60
LVMi > 125 g/m
2
LVMi > 51 g/m
2.7
5.6
8.3
9.5
11.7
25.3
48.4
N = 4176 hypertensive subjects
Normal weight = 26.3 %
Overweight = 50.0 %
Obese = 23.7 %
P
r
e
v
a
le
n
c
e
 o
f
 L
V
H
 (
%
)
Figure 4 Prevalence of LVH in hypertensive subjects, based
on normalization for BSA (dotted columns) or height2.7 (black-
squared columns). Prevalence of LVH in obese normotensive
subjects is only slightly less than in normal-weight hyperten-
sive subjects. Adapted from population in Ref. [94].
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+ MODELStudy [26], a population-based study with very high prev-
alence of obesity, in which the variance of LV mass was
explained by abdominal fat rather than insulin resistance.
This finding suggests that visceral fat-related stimuli other
than insulin might have more impact on LV geometric
changes.
The association of increased LV mass with the obesity-
related inflammatory state is particularly relevant. It has been
recently suggested that LVH in obesity might be expression of
the systemic inflammation, likely through contributing to the
increase in tissue water content and reactive fibrosis [22].
There is evidence that structural modifications occur
even in moderately obese individuals [28], attributable to
increased fibrosis, an evidence already reported in nec-
ropsy studies. In addition to the increased fibrosis, there is
also evidence that, accompanying the excess of abdominal
fat, epicardial fat is increased in obese subjects and is
related to increased LV mass [29]. In addition to the po-
tential neuro-hormonal stimulation induced by the visceral
fat surrounding epicardium, physical alterations induced by
fat accumulation contribute to the structural abnormalities
of myocardium [30]. Fat accumulating at the epicardial
level infiltrates the myocardium [30], contributing to the
obesity-related structural and functional abnormalities.
Moreover, similar to other organs, exposure of the heart
to high levels of free fatty acids alters microscopic cytosolic
characteristics of non-adipose tissues near to mitochondria,
and impairs mitochondrial function, with structural and
functional consequences also during youth [31]. Thus, the
increased LV mass in obesity is the consequence of a gen-
eral, inappropriate increase of all myocardial cell compo-
nents and composition, yielding a global alteration of the
normal structure of myocardium.Please cite this article in press as: de Simone G, et al., Left ventricular
& Cardiovascular Diseases (2013), http://dx.doi.org/10.1016/j.numecThe complex of the non-hemodynamic components of
the increase in myocardial mass might explain, at least in
part, also the reported obesity-associated right ventricular
hypertrophy, which is correlated with BMI as much as LV
hypertrophy [32], and the evidence of LV mass inappropri-
ately high for the magnitude of hemodynamic load [33,34].
The relative hemodynamic-independence of these
myocardial modifications well explains the early LV geo-
metric abnormalities detected in overweight children and
adolescents, before a significant impact of blood pressure
rise can be detected [11].
The pathophysiology of increase in LV mass in obesity
suggests that the definition of LV hypertrophy for this in-
crease might be misleading, as it might incorrectly address
to the concept of cardiomyocyte hypertrophy, which is only
one of the components of the increased myocardial mass
and probably not the most important at least when pressure
load is normal. When arterial hypertension develops,
pressure overload is the additional stimulus that adds to the
other obesity-related stimuli with an exponential effect on
prevalence of LV hypertrophy [35,36] (Fig. 4). Thus, the
association of obesity with hypertension combines pressure
and volume overload together with a number of non-
hemodynamic stimuli enhancing LV myocardial growth,
with severe prognostic implications [37].Prevalence of LV hypertrophy in obesity
Even in the absence of hypertension, obesity is frequently
associated with non-optimal BP values [38], which con-
tributes to increasing LV mass and to the prevalence of LV
hypertrophy. However, assessment of LV hypertrophy in the
presence of obesity is a difficult task, due to the abnormal
body composition of obese subjects. To compare the level
of LV mass with normal reference, normalization for body
size is needed. The traditional method to normalize for
body size has utilized body surface area (BSA) and, most
commonly, the DuBois & DuBois formula, though it has
never been validated in obesity. However, as highlighted in
many articles [39e41], use of BSA as the measure of bodygeometry in obesity: Is it what we expect?, Nutrition, Metabolism
d.2013.06.012
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adjustment, due to the adipose component of the body
composition, which has an impact on LV mass substantially
different from lean body mass.
Based on comparative physiology studies in mammals
[42,43], and on equations developed in a large normoten-
sive and normal-weight reference population sample,
encompassing the entire life-span, we proposed in 1992 to
normalize LV mass for height in meters to the power of 2.7
[40]. This allometric signal appeared geometrically consis-
tent, as relating a three-dimensional with a one-
dimensional variable, which are linearly related at power
of 3. Other studies have shown afterward that the allo-
metric signal is lower than initially reported when only the
adulthood is analyzed [44e46], as well as higher (i.e. 3)
when only children during body growth are analyzed [47].
The apparent inconsistency is substantially due to the
different age-related intra-population variability of height.
Compared to the normalization of LV mass for BSA, nor-
malization for height in m2.7 identifies a much greater
prevalence of LV hypertrophy in obese subjects [48] (Fig. 4).
Using LV mass/height2.7, the prevalence of LV hypertrophy
ranges between 13% in obese, normotensive individuals [10]
and over 75% in individuals with morbid obesity, in the pres-
ence of hypertension [35], with only a modest decrease in the
hazard ratio for incident cardiovascular morbidity, compared
to normalization with BSA [48,49]. As a consequence, in pop-
ulationswith a large prevalence of obesity, thepopulation risk
attributable to LV hypertrophy that is identified with
normalization of LV mass for height2.7 is substantially greater
(17%) than with normalization for BSA (10%) or even the linear
measure of height [48].
Most recently, Chirinos et al. [45] found a substantially
lower allometric signal (i.e. 1.7) in the MESA, a large multi-
ethnic population-based study, which was prognostically
relevant. They also identified a strong residual negative
correlation between LV mass/height2.7 and height, which
was not evident using the MESA-generated allometric signal
“1.7”. This residual negative relation was also confirmed in
the Strong Heart Study population, but in that population,
characterized by an overwhelming prevalence of obesity,
the LV mass index using height1.7 did not produce significant
hazard ratio and a low population attributable risk [50].
The substantial difference between the original indication
of the utility of allometric equations [40] and the lower
allometric signals reported afterward [44e46] is that the
first equation was obtained merging infants, children, ad-
olescents and adults, while the subsequent analyses have
been performed within adult populations (therefore with
substantial less variability of height), in whom a smaller
exponent reflects a substantially lower variability of the
independent variable.
An interesting hypothesis, however, is that when using
greater allometric signals (2.7), obtained across the entire
age-span and producing the negative residual relation with
height, the prognostic effect of LV mass index is also
tracked by lower body height [51]. This hypothesis is based
on the evidence that height seems to be a predictor of
cardiovascular morbidity and mortality in a relevant num-
ber of epidemiological studies [52,53], though this evidence
is contradicted by other studies [54]. A recent meta-
analysis performed in a large number of studies, carefullyPlease cite this article in press as: de Simone G, et al., Left ventricular
& Cardiovascular Diseases (2013), http://dx.doi.org/10.1016/j.numecselected, confirmed the association of low height with
prognosis [54]. Whether body height tracks prognostic in-
formation obtained by LV mass index by the greatest allo-
metric signals of height remains to be explored.
As today, the suggested partition values for LV hyper-
trophy in obese adults is not different from the ones sug-
gested for the general population: 50 g/m2.7 in men and
47 g/m2.7 in women.LV geometry in obesity
What is certain at this time is that using BSA to normalize LV
mass in obesity may potentially lead to substantial errors.
Lavie et al. [55] evaluated LV geometry in a large popula-
tion sample of obese subjects with preserved ejection
fraction, referred for echocardiographic exam to their in-
stitutions. Prevalence of hypertension was not reported. LV
mass was normalized for BSA. The authors found a very low
prevalence of clear-cut LV hypertrophy (7% for eccentric
and 8% for concentric LV hypertrophy) with an over-
whelming prevalence of concentric LV remodeling (34%), a
geometric pattern associated with low cardiac output and
high peripheral resistance [56,57]. Similar to other results
obtained using BSA as the measure of body size to
normalize LV mass, the Lavie’s results could be substan-
tially different with normalizations of LV mass for height2.7,
because many observations with concentric LV remodeling
could shift to the concentric LV hypertrophy pattern.
However, what this study highlights is the very high prev-
alence of concentric LV geometry (i.e. combined remod-
eling and hypertrophy) in obese subjects, an evidence that
confirms, on a larger scale, previous and more recent
findings [10,32,58] and contributes to shake the paradigm
of the association of obesity with eccentric LV hypertrophy
[59,60]. A strong confirmation of the association of obesity
with concentric LV geometry was recently produced using
magnetic resonance imaging in the MESA [61].
Mechanisms of development of concentric LV geometry
in a high-output state such as obesity are unclear, but there
are many potential stimuli orienting toward a concentric
geometric pattern of LV adaptation in obesity [12,13].
Also the non-muscular components of the increased LV
mass may thicken LV wall more than expected for the he-
modynamic load. An inappropriately elevated LV mass rela-
tively to the hemodynamic load (a condition associated with
severe degrees of concentric LV geometry) has been re-
ported in obesity [33,34]. Fat tissue infiltrating myocardium
has physical characteristics different from muscular tissue,
the most important of which is elasticity. Fat is a scarcely
elastic tissue [62,63] and infiltration into the myocardium has
to alter the tissue elastic properties, likely impairing
distensibility and limiting LV dilatation. Cytosolic accumula-
tion of fatty acid increases the size of cardiomyocytes
independently of expression of sarcomeres [30,64] and,
possibly, reduces cell elastance. In addition to promoting
reactive fibrosis, overproduction of cytokines from the
visceral adipose tissue, namely from the IL6 family, may also
contribute to sarcomeric growth in both serial and parallel
directions [65e67].
Moreover, in comparable conditions, in obese subjects
classified as normotensive, blood pressure is almostgeometry in obesity: Is it what we expect?, Nutrition, Metabolism
d.2013.06.012
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predicts the incidence of overt arterial hypertension [11,38].
Hemorheologic components of total peripheral resistance
influence native blood pressure [68], are associated with
concentric LV geometry [69] and are altered in obesity [70].
Thus, pressure load in obese individuals is constantly higher
than in normal-weight persons, even in the presence of
normal blood pressure values, and might well direct the
sarcomeric expression toward a parallel pattern. Yet,
assessment of normal blood pressure in office, does not
exclude at all the presence of daily hypertension. Masked
hypertension is more frequent in obese than in normal-
weight individuals [71]. Eventually, other specific condi-
tions, associated with obesity, such as sleep apnea syn-
drome, contribute to explaining the prevalence of concentric
LV geometry in this condition [72], by increasing the pressure
overload during night.
The interesting aspect of concentric LV hypertrophy in
obese individuals is the combination with a high-output state
[7]. Although the increase in cardiac output is less than in
obese individuals with eccentric LV hypertrophy, concentric
LV hypertrophy in obesity does not follow the simple para-
digm that we have proposed in 1992 [56], further elaborated
later [73]. Concentric LV hypertrophy in obesity is most often
associated with some degree of LV dilatation, even in the
presence of normal LV chamber function, which strongly
suggests a combined volume and pressure overload with
particular functional consequences [74].
Sex-differences in obesity-related LV
geometry
Body composition is different in women and men. In the
Strong Heart Study, for each kg/m2 of BMI, adipose tissue
was substantially more abundant in women than in men
[75]. Though lower than in men in absolute terms, in the
Strong Heart Study, LV mass was actually greater in obese
women than in obese men when normalized for height2.7
(Fig. 5), whereas the effects of both sex and obesity were
not detected when using normalization for BSA. Similarly,
when LV mass was normalized for fat-free mass, obese
women also exhibited greater values than men [75,76].
While BMI was not independently associated with LV mass inFigure 5 Mean and standard deviation of LV mass normalized
by height in m2.7 in non-obese and obese men and women,
participants of the Strong Heart Study cohort. From Table 3 of
Ref. [75].
Please cite this article in press as: de Simone G, et al., Left ventricular
& Cardiovascular Diseases (2013), http://dx.doi.org/10.1016/j.numecboth genders, adipose mass and waist-to-hip ratio gave
significant contribution to variability of LV mass in women
but not in men, independently of the other physiological
contributors (age, fat-free mass, systolic BP, hypertension
and stroke volume) [75], a finding also reported in different
ethnic groups [77] and in different contexts, and confirmed
in a magnetic resonance study [78].
Menopause does not appear to have substantial effect on
the obesity-related sex-differences in LV mass [75],
whereas it is one of the factors associated with the greater
rate of concentric LV geometry in women [79].
Because fat-free mass is substantially less in obese
women than in obese men, it would be unrealistic to inter-
pret the increased LV mass index found in obese women as
predominantly due to cardiomyocyte hypertrophy, whereas
it is more likely related to non-muscular components of
myocardium. As said above, central obesity is associated
with activation of inflammatory markers [3,4,80] that can
contribute to explaining also this gender-related differences
[81]; this is consistent with the evidence that Strong Heart
Study women exhibited higher levels of inflammatory
markers than men. In a small series of normotensive obese
women several markers of inflammation were correlated
either with LV mass index and with visceral fat [66].LV mass and weight loss
Reduction of LV hypertrophy in obese individuals is an
achievable objective with significant weight loss [82,83]. This
association is suggested to be even more evident than the
association of decrease in LV mass with decrease in blood
pressure [84]. In a large population of high-risk hypertensive
patients, for comparable decrease in blood pressure, LV mass
was substantially less reduced when obesity was present
[85e87]. If not managed, obesity is also a strong obstacle
opposing to the possibility of optimal blood pressure control
by antihypertensive medications [88]. Also, in the hyper-
tensive participants of the Strong Heart Study cohort, obesity
is associated with lack of decrease, or even increase, in LV
mass index over time, independently of blood pressure
control and antihypertensive therapy [89].
The clear effect of weight loss on reduction of LV mass
has been more recently confirmed in series of obese pa-
tients undergone bariatric surgery [90,91]. Although the
reduction of LV mass observed with bariatric surgery is of
similar magnitude as that obtained with sustained diet-
induced weight loss [91], maintenance of a target body
weight after surgery is easier than keeping patients on diet,
though this advantage should be weighted by the potential
complications and side-effect of surgical procedures in the
long run. In contrast, aggressive antihypertensive treat-
ment in hypertensive patients with LV hypertrophy was
associated with impaired reduction in LV mass and less
improvement in systolic LV function in obese compared to
normal-weight subjects, despite comparable blood pres-
sure reduction [86].
Mechanisms of improvement of LV geometry with weight
loss are primarily hemodynamic, through a substantial
reduction of stroke work, but also involve directly
myocardial fatty acid uptake and reduction of myocardial
triglyceride content [92]. These changes associated withgeometry in obesity: Is it what we expect?, Nutrition, Metabolism
d.2013.06.012
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+ MODELweight loss might also be macroscopically observed with
the substantial reduction of epicardial fat, detected by 2D
echocardiography [93].Conclusions
Obesity is a major cause of LV hypertrophy, which is sus-
tained by the increased hemodynamic load and non-
muscular components of myocardium, through mecha-
nisms involving visceral adipose tissue. LV hypertrophy is
often concentric and more pronounced in obese women
than in men. Weight loss is a stimulus to reduce LV mass at
least as potent as reduction in blood pressure. Given the
complex mechanism involved in the development of LV
hypertrophy in obesity, it could be predictable that pure
interventions on hemodynamic load could not have sub-
stantial effect on reduction of LV mass [85e87]. If LV hy-
pertrophy reduction is a target in the management of
obesity, non-hemodynamic factors should have the same
degree of attention as the hemodynamic load.References
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